Browse by category

Ascletis Pharma has completed enrolment in its 13-week US Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of type 2 diabetes mellitus (T2D). T2D is the second indication for ASC30, following its first indication of obesity. Topline data from the Phase II study for the treatment of T2D are expected in the third quarter of 2026. The Phase II study is a 13-week, randomised, double-blind, placebo-controlled and multi-cent

The first participants have been dosed in Ascletis Pharma’s US 13-week Phase II study with ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes mellitus. Topline data from the Phase II study are expected in the third quarter of 2026. Ascletis recently completed a 13-week Phase II study evaluating ASC30 for the treatment of obesity in 125 participants with obesity or overweight with at least one weight-related comorbidity at multip

Ascletis Pharma has completed enrolment in the US Phase IIa study for its once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity. All 65 participants are obese or overweight with at least one weight-related comorbidity. The Phase IIa study of ASC30 once-monthly SQ depot treatment formulation is a 12-week, randomised, double-blind, placebo-controlled and multi-centre study co

Ascletis Pharma’s ASC47, a muscle-preserving weight loss drug candidate, in combination with semaglutide demonstrated up to 56.2% greater...

Ascletis Pharma has completed enrolment in its US 13-week Phase IIa study evaluating ASC30, a small molecule oral GLP-1 receptor (GLP-1R)...

The first participants with obesity or overweight with at least one weight-related comorbidity have been dosed in Ascletis Pharma’s US...

Ascletis Pharma has announced pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies in...

Ascletis Pharma has revealed positive interim results from the first two cohorts of its randomised, double-blind, placebo-controlled...

Ascletis Pharma has announced positive topline results from its US single ascending dose (SAD) study of ASC30 oral tablet in patients...

Ascletis Pharma has revealed in a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg,...